Mperia Therapeutics Adds Experts in Drug Delivery, Dry AMD & Atherosclerosis to CAB
CEO & President Paul Chipperton is pleased to announce today the appointment of Dr Daniel Saban, PhD; Dr Szilard Voros PhD, MD; and Dr Jean-Christophe Leroux, PhD; to the company’s Clinical Advisory Board (CAB). He commented “all three bring complementary applied Ophthalmology, Cardiovascular, and Drug Delivery expertise respectively to the clinical development of our CD36 receptor drug candidates. They will join our scientific founder Dr Huy Ong in accelerating our programs.”
Dr. Saban, PhD is an Associate Professor of Ophthalmology and Immunology at Duke University. He received his PhD from the University of Florida in Immunological Sciences, and completed his postdoctoral fellowship at Harvard Medical School, Mass. Eye and Ear Infirmary in Ocular Immunology. Currently, Dr. Saban serves as Scientific Director of the Foster Center for Ocular Immunology at the Duke Eye Center, as well as the co-Director of the Neuroimmunology and Glia Group at the Duke Institute for Brain Sciences, and is a member of the Annual Meeting Programs Committee for the Immunology and Microbiology section for the Association for Research in Vision and Ophthalmology (ARVO). Dr. Saban’s lab studies the role of myeloid cells in the context of eye and retinal disease (Reyes et al, Nature Reviews Immunology. 2017). His lab recently discovered (Reyes et al, Science Translational Medicine. 2018) a role for neutrophils in driving Meibomian gland dysfunction (MGD), the leading cause of Dry Eye Disease.
Dr. Voros, PhD, MD is a trained cardiologist and geneticist, formerly as Chief of Cardiovascular Prevention and Medical Director of Cardiovascular Imaging at Piedmont Heart Institute, Atlanta. Subsequently he founded and became CEO of Global Genomics Group (“G3”), a precision-medicine-based biotechnology company, developing and commercializing diagnostic biomarkers and novel drug targets for common diseases. G3 has developed a diagnostic blood test for cardiovascular disease and has identified several novel drug targets. He has published extensively in major scientific journals including: Nature Reviews, New England Journal of Medicine, Annals of Internal Medicine, Journal of the American College of Cardiology and Circulation: Cardiovascular Genetics.
“I am very enthusiastic about exploring the therapeutic modulation of the CD36 pathway to impact major unmet medical needs such as dry AMD, atherosclerotic heart disease and fatty liver disease. The CD36 pathway uniquely sits at the intersection of lipid metabolism, innate immunity and inflammation, opening the opportunity to modulate a number of disease conditions where these pathways are dysregulated. Mperia Therapeutics has a pipeline of compounds in development to modulate the CD36 pathway and I am keen to see much needed therapeutic solutions delivered to patients as a result of this program,” said Dr Voros.
Dr Leroux, PhD is the Chairman of Mperia Therapeutics’ CAB. He has significant therapeutic development experience as the co-founder and SAB member of current Switzerland-based start-up companies: Versantis AG and Inositec AG. His research interests include the design of novel biopolymers, drug delivery systems, the targeting of anti-cancer drugs and formulation of peptidic molecules. After spending more than ten years as Professor at the University of Montreal, Pharmacy School, he crossed the Atlantic in 2008 to accept an appointment of Full Professor at ETH Zurich. Dr Leroux published more than 200 peer-reviewed scientific papers in international journals and supervised about 70 combined Ph.D. students and postdoctoral trainees.
ABOUT MPERIA THERAPEUTICS
Mperia Therapeutics is the CD36 Therapeutics Company which focuses on macrophage-driven inflammation. The technology basis resides in highly specific CD36 receptor cyclic peptides which modulate the inflammasome in addition to modifying macrophages’ metabolic dysfunction with outstanding anti-inflammatory response. Mperia holds exclusive rights to various highly efficacious CD36 receptors ligands against dAMD and atherosclerosis.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181204005736/en/